Basal Expression of Insulin-like Growth Factor 1 Receptor Determines Intrinsic Resistance of Cancer Cells to a Phosphatidylinositol 3-kinase Inhibitor ZSTK474

Overview

Journal Cancer Sci

Specialty Oncology

Date 2014 Dec 9

PMID 25483727

Citations 9

Authors

Sho Isoyama

Gensei Kajiwara

Naomi Tamaki

Mutsumi Okamura

Hisashi Yoshimi

Naoki Nakamura

Kento Kawamura

Yumiko Nishimura

Nachi Namatame

Takao Yamori

Shingo Dan

Affiliations

Soon will be listed here.

Abstract

Drug resistance often critically limits the efficacy of molecular targeted drugs. Although pharmacological inhibition of phosphatidylinositol 3-kinase (PI3K) is an attractive therapeutic strategy for cancer therapy, molecular determinants for efficacy of PI3K inhibitors (PI3Kis) remain unclear. We previously identified that overexpression of insulin-like growth factor 1 receptor (IGF1R) contributed to the development of drug resistance after long-term exposure to PI3Kis. In this study, we examined the involvement of basal IGF1R expression in intrinsic resistance of drug-naïve cancer cells to PI3Kis and whether inhibition of IGF1R overcomes the resistance. We found that cancer cells highly expressing IGF1R showed resistance to dephosphorylation of Akt and subsequent antitumor effect by ZSTK474 treatment. Knockdown of IGF1R by siRNAs facilitated the dephosphorylation and enhanced the drug efficacy. These cells expressed tyrosine-phosphorylated insulin receptor substrate 1 at high levels, which was dependent on basal IGF1R expression. In these cells, the efficacy of ZSTK474 in vitro and in vivo was improved by its combination with the IGF1R inhibitor OSI-906. Finally, we found a significant correlation between the basal expression level of IGF1R and the inefficacy of ZSTK474 in an in vivo human cancer panel, as well as in vitro. These results suggest that basal IGF1R expression affects intrinsic resistance of cancer cells to ZSTK474, and IGF1R is a promising target to improve the therapeutic efficacy. The current results provide evidence of combination therapy of PI3Kis with IGF1R inhibitors for treating IGF1R-positive human cancers.

Citing Articles

Genomic landscape of mature B-cell non-Hodgkin lymphomas - an appraisal from lymphomagenesis to drug resistance.

Panda D, Das N, Thakral D, Gupta R J Egypt Natl Canc Inst. 2022; 34(1):52.

PMID: 36504392 DOI: 10.1186/s43046-022-00154-z.

Drug Resistance in Non-Hodgkin Lymphomas.

Klener P, Klanova M Int J Mol Sci. 2020; 21(6).

PMID: 32197371 PMC: 7139754. DOI: 10.3390/ijms21062081.

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer.

Hashemzadeh K, Jokar M, Sedighi S, Moradzadeh M Middle East J Dig Dis. 2019; 11(1):5-16.

PMID: 31049177 PMC: 6488499. DOI: 10.15171/mejdd.2018.122.

Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.

Namatame N, Tamaki N, Yoshizawa Y, Okamura M, Nishimura Y, Yamazaki K Oncotarget. 2018; 9(80):35141-35161.

PMID: 30416685 PMC: 6205545. DOI: 10.18632/oncotarget.26216.

Absence of renal enlargement in fructose-fed proximal-tubule-select insulin receptor (IR), insulin-like-growth factor receptor (IGF1R) double knockout mice.

Li L, Byrd M, Doh K, Dixon P, Lee H, Tiwari S Physiol Rep. 2016; 4(23).

PMID: 27923977 PMC: 5357825. DOI: 10.14814/phy2.13052.

References

Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K . Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res. 1999; 59(16):4042-9. View

Shepherd P, Withers D, Siddle K . Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J. 1998; 333 ( Pt 3):471-90. PMC: 1219607. DOI: 10.1042/bj3330471. View

Harrington L, Findlay G, Lamb R . Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci. 2005; 30(1):35-42. DOI: 10.1016/j.tibs.2004.11.003. View

Zick Y . Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE. 2005; 2005(268):pe4. DOI: 10.1126/stke.2682005pe4. View

Sarbassov D, Guertin D, Ali S, Sabatini D . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098-101. DOI: 10.1126/science.1106148. View

OReilly K, Rojo F, She Q, Solit D, Mills G, Smith D . mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66(3):1500-8. PMC: 3193604. DOI: 10.1158/0008-5472.CAN-05-2925. View

Lievre A, Bachet J, Le Corre D, Boige V, Landi B, Emile J . KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66(8):3992-5. DOI: 10.1158/0008-5472.CAN-06-0191. View

Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H . Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst. 2006; 98(8):545-56. DOI: 10.1093/jnci/djj133. View

Engelman J, Luo J, Cantley L . The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-19. DOI: 10.1038/nrg1879. View

10.

Wan X, Harkavy B, Shen N, Grohar P, Helman L . Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2006; 26(13):1932-40. DOI: 10.1038/sj.onc.1209990. View

11.

Engelman J, Chen L, Tan X, Crosby K, Guimaraes A, Upadhyay R . Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14(12):1351-6. PMC: 2683415. DOI: 10.1038/nm.1890. View

12.

Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y . Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol. 2009; 16(2):161-7. DOI: 10.1111/j.1442-2042.2008.02224.x. View

13.

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

14.

Gridelli C, Rossi A, Bareschino M, Schettino C, Sacco P, Maione P . The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs. 2010; 19(5):631-9. DOI: 10.1517/13543781003767434. View

15.

Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M . Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res. 2010; 70(12):4982-94. DOI: 10.1158/0008-5472.CAN-09-4172. View

16.

Sachdev D . Targeting the type I insulin-like growth factor system for breast cancer therapy. Curr Drug Targets. 2010; 11(9):1121-32. DOI: 10.2174/138945010792006816. View

17.

Rosenzweig S, Atreya H . Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 2010; 80(8):1115-24. PMC: 2934757. DOI: 10.1016/j.bcp.2010.06.013. View

18.

Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V . AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011; 19(1):58-71. PMC: 3025058. DOI: 10.1016/j.ccr.2010.10.031. View

19.

Philip R, Carrington L, Chan M . US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics. Bioanalysis. 2011; 3(4):383-9. DOI: 10.4155/bio.11.1. View

20.

Shuttleworth S, Silva F, Cecil A, Tomassi C, Hill T, Raynaud F . Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem. 2011; 18(18):2686-714. PMC: 3228236. DOI: 10.2174/092986711796011229. View